Thompson, M., Tam, C., Wu, K., Patel, S., Takai, M., Phuong, P., Rose, S., Levin, M., Munir, T., Ghia, P., Seymour, J. (2025). CaDAnCe-304, a phase 3, open-label, randomized study to evaluate the safety and efficacy of Bruton tyrosine kinase degrader BGB-16673 compared with pirtobrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Blood. https://doi.org/10.1182/blood-2025-5691